Wells Fargo & Company Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its price target raised by Wells Fargo & Company from $31.00 to $44.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 22.12% from the company’s previous close.

Several other brokerages also recently issued reports on LQDA. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. BTIG Research boosted their price objective on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research note on Thursday. Finally, Jefferies Financial Group raised their target price on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, January 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Liquidia Price Performance

LQDA opened at $36.03 on Friday. Liquidia has a 52-week low of $11.26 and a 52-week high of $46.67. The company has a 50 day moving average of $37.10 and a two-hundred day moving average of $30.92. The company has a market cap of $3.13 billion, a P/E ratio of -43.41, a P/E/G ratio of 0.62 and a beta of 0.52. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The business had revenue of $92.02 million during the quarter. Liquidia had a negative net margin of 43.53% and a negative return on equity of 237.79%. The company’s quarterly revenue was up 3072.4% on a year-over-year basis. On average, analysts expect that Liquidia will post -1.51 earnings per share for the current year.

Insider Activity

In other Liquidia news, insider Jason Adair sold 688 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $28,655.20. Following the transaction, the insider owned 211,169 shares in the company, valued at $8,795,188.85. The trade was a 0.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Russell Schundler sold 27,289 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the completion of the transaction, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. The trade was a 4.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 212,534 shares of company stock worth $7,964,719 over the last three months. 26.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia during the 4th quarter valued at approximately $25,000. Covestor Ltd raised its position in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the 3rd quarter valued at approximately $34,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Liquidia during the second quarter worth approximately $25,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).